ArticleCureus2025
A Retrospective Quantitative Analysis of the Shared Care Glaucoma Scheme (SCGS) in Monitoring Glaucoma Progression During COVID-19.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the impact of the shared care glaucoma scheme (SCGS), implemented during COVID-19 due to reduced clinic space and lockdown measures, on glaucoma disease progression in patients.
backgroundThe study was conducted between January 2021 and December 2023 and explored joint care provided by ophthalmologists and community optometrists in Lothian.
methodsData collected include patient demographics, intraocular pressure (IOP) readings, mean deviation visual field scores (MDVFs), a history of interventions during the pre-SCGS phase, glaucoma medications, and referrals to Princess Alexandra Eye Pavilion (PAEP). The IOP, MDVF, and glaucoma medications were collected at three stages: pre-SCGS, SCGS, and post-SCGS. The Glauc-Strat-Fast tool was used to assign each patient a pre-SCGS glaucoma stage.
resultsA total of 172 patients (85 males, 49.4%) participated in this study, with a mean age of 77.7 years (SD = 10.4). Sixteen patients (9.30%) were referred to PAEP during the scheme; the Red group of patients, identified using the Glauc-Strat-Fast tool, represented five of these referrals (31.3%). Four of the referred patients (25%) had an intervention at PAEP, either a change in medication or a surgical procedure. There was no significant increase in the IOP values from the pre-SCGS phase to the post-SCGS phase. The MDVF values had a mean deterioration of 0.5998 dB from the pre-SCGS phase to the post-SCGS phase.
conclusionsOverall, disease stability was maintained in all glaucoma subgroups. The study, therefore, suggests the possibility of implementing the SCGS in the United Kingdom as part of routine glaucoma service in the post-COVID-19 era.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.